Breaking News

Isogenica Names CEO

August 28, 2014

Ullman replaces Matthews

Dr. Chris Ullman has been appointed chief executive officer of Isogenica. Dr. Ullman replaces Dr. Kevin Matthews who is leaving the company to pursue other opportunities.
 
Dr. Ullman has been with the company since 2002 and has served as chief scientific officer since 2009. He has been instrumental in developing Isogenica’s strategy and driving its technologies.
 
“Dr. Ullman has worked closely with Dr. Matthews over the last five years and has been at the heart of delivering a fundamental change in the capability and direction of the business. I am sure that Chris will be successful in further developing Isogenica to provide technologies and technology capabilities that are valued by its pharma and biotech partners and academic collaborators,” said Jan-Olof Lundin, Chairman of Isogenica.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks